Pharmaceuticals

Vyvgart Market 2026 gaining momentum with autoimmune disease therapies

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Vyvgart Market Expected To Change Between 2026 And 2030?

Historically, the observed growth was driven by an enhanced comprehension of autoimmune disease mechanisms, the authorization of novel biologic therapies, a rise in the diagnosis rates for gMG, the expansion of specialized neurology care, and the accessibility of advanced antibody treatments.

The anticipated growth during the forecast period is primarily driven by the expansion of treatment indications beyond gMG, the increasing embrace of precision immunology treatments, growing investments within the autoimmune biologics sector, a rising demand for options providing long-term disease control, and the development of next-generation FcRn inhibitors. Concurrently, major trends expected within the forecast timeframe include the expanding adoption of FcRn inhibitor therapies, an increasing focus on targeted autoimmune disease treatments, the growing clinical application of antibody reduction mechanisms, a rising demand for personalized immunotherapy solutions, and an enhanced emphasis on protracted disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20394&type=smp

What Underlying Factors Are Accelerating The Growth Of The Vyvgart Market?

The rising incidence of autoimmune diseases is projected to stimulate the expansion of the vyvgat market moving forward. Autoimmune conditions are characterized by the body’s immune system mistakenly attacking its own healthy cells and tissues, perceiving them as foreign or harmful. The increase in autoimmune diseases is largely attributed to a combination of genetic predisposition, environmental factors, infections, and lifestyle changes, such as diet and greater exposure to chemicals. Vyvgart (efgartigimod alfa-fcab) is utilized in the treatment of autoimmune diseases, specifically generalized myasthenia gravis (gMG), by targeting and inhibiting the neonatal Fc receptor (FcRn) to reduce pathogenic antibodies contributing to the condition. For instance, in August 2024, the Myasthenia Gravis Foundation of America, a US-based organization, reported that myasthenia gravis affects approximately 150 to 200 individuals per million people worldwide. In the United States, it is estimated that 37 out of every 100,000 people have the condition. Therefore, the escalating prevalence of autoimmune diseases is a significant driver for the vyvgat market.

How Is The Vyvgart Market Structured Across Different Segments?

The vyvgart market covered in this report is segmented –

1) By Indication: Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

2) By End User: Adult, Geriatric

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Trends Are Shaping The Future Of The Vyvgart Market?

A predominant trend within the vyvgart market involves prioritizing the acquisition of regulatory approvals to secure a competitive advantage. These endorsements are vital for confirming Vyvgart’s safety and effectiveness in treating autoimmune diseases. They also enhance the drug’s availability in the market and strengthen confidence among physicians and patients. For instance, in March 2024, argenx, an immunology firm headquartered in the Netherlands, announced that its innovative treatment, VYVGART (efgartigimod alfa), received approval in Japan for adults suffering from primary immune thrombocytopenia (ITP). This clearance, issued by Japan’s Ministry of Health, Labour and Welfare, represents VYVGART’s inaugural global approval specifically for ITP, expanding its therapeutic applications beyond generalized myasthenia gravis (gMG), for which it already holds approvals in diverse territories such as the United States and Europe. VYVGART functions as a human IgG1 antibody fragment designed to target the neonatal Fc receptor (FcRn), leading to a reduction in circulating IgG autoantibodies. This mechanism offers a novel therapeutic alternative for individuals who have been seeking effective treatments for this autoimmune condition.

Which Major Players Dominate The Vyvgart Market?

Major companies operating in the vyvgart market are Argenx SE

Read the full vyvgart market report here:

https://www.thebusinessresearchcompany.com/report/vyvgart-global-market-report

Which Region Is Projected To Dominate The Vyvgart Market During The Forecast Period?

North America was the largest region in the vyvgart market in 2025. The regions covered in the vyvgart market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vyvgart Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20394&type=smp

Browse Through More Reports Similar to the Global Vyvgart Market 2026, By The Business Research Company

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Supermarkets And Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/supermarkets-and-hypermarkets-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795